BACKGROUND: Timing of initiation of screening for breast cancer is controversial in the United States. OBJECTIVE: To determine the threshold relative risk (RR) at which the harm-benefit ratio of screening women aged 40 to 49 years equals that of biennial screening for women aged 50 to 74 years. DESIGN: Comparative modeling study. DATA SOURCES: Surveillance, Epidemiology, and End Results program, Breast Cancer Surveillance Consortium, and medical literature. TARGET POPULATION: A contemporary cohort of women eligible for routine screening. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Mammography screening starting at age 40 versus 50 years with different screening methods (film, digital) and screening intervals (annual, biennial). BENEFITS: life-years gained, breast cancer deaths averted; harms: false-positive mammography findings; harm-benefit ratios: false-positive findings/life-years gained, false-positive findings/deaths averted. RESULTS OF BASE-CASE ANALYSIS: Screening average-risk women aged 50 to 74 years biennially yields the same false-positive findings/life-years gained as biennial screening with digital mammography starting at age 40 years for women with a 2-fold increased risk above average (median threshold RR, 1.9 [range across models, 1.5 to 4.4]). The threshold RRs are higher for annual screening with digital mammography (median, 4.3 [range, 3.3 to 10]) and when false-positive findings/deaths averted is used as an outcome measure instead of false-positive findings/life-years gained. The harm-benefit ratio for film mammography is more favorable than for digital mammography because film has a lower false-positive rate. RESULTS OF SENSITIVITY ANALYSIS: The threshold RRs changed slightly when a more comprehensive measure of harm was used and were relatively insensitive to lower adherence assumptions. LIMITATION: Risk was assumed to influence onset of disease without influencing screening performance. CONCLUSION: Women aged 40 to 49 years with a 2-fold increased risk have similar harm-benefit ratios for biennial screening mammography as average-risk women aged 50 to 74 years. Threshold RRs required for favorable harm-benefit ratios vary by screening method, interval, and outcome measure. PRIMARY FUNDING SOURCE: National Cancer Institute.
BACKGROUND: Timing of initiation of screening for breast cancer is controversial in the United States. OBJECTIVE: To determine the threshold relative risk (RR) at which the harm-benefit ratio of screening women aged 40 to 49 years equals that of biennial screening for women aged 50 to 74 years. DESIGN: Comparative modeling study. DATA SOURCES: Surveillance, Epidemiology, and End Results program, Breast Cancer Surveillance Consortium, and medical literature. TARGET POPULATION: A contemporary cohort of women eligible for routine screening. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Mammography screening starting at age 40 versus 50 years with different screening methods (film, digital) and screening intervals (annual, biennial). BENEFITS: life-years gained, breast cancer deaths averted; harms: false-positive mammography findings; harm-benefit ratios: false-positive findings/life-years gained, false-positive findings/deaths averted. RESULTS OF BASE-CASE ANALYSIS: Screening average-risk women aged 50 to 74 years biennially yields the same false-positive findings/life-years gained as biennial screening with digital mammography starting at age 40 years for women with a 2-fold increased risk above average (median threshold RR, 1.9 [range across models, 1.5 to 4.4]). The threshold RRs are higher for annual screening with digital mammography (median, 4.3 [range, 3.3 to 10]) and when false-positive findings/deaths averted is used as an outcome measure instead of false-positive findings/life-years gained. The harm-benefit ratio for film mammography is more favorable than for digital mammography because film has a lower false-positive rate. RESULTS OF SENSITIVITY ANALYSIS: The threshold RRs changed slightly when a more comprehensive measure of harm was used and were relatively insensitive to lower adherence assumptions. LIMITATION: Risk was assumed to influence onset of disease without influencing screening performance. CONCLUSION:Women aged 40 to 49 years with a 2-fold increased risk have similar harm-benefit ratios for biennial screening mammography as average-risk women aged 50 to 74 years. Threshold RRs required for favorable harm-benefit ratios vary by screening method, interval, and outcome measure. PRIMARY FUNDING SOURCE: National Cancer Institute.
Authors: Katrina Armstrong; Elizabeth Moye; Sankey Williams; Jesse A Berlin; Eileen E Reynolds Journal: Ann Intern Med Date: 2007-04-03 Impact factor: 25.391
Authors: Amir Qaseem; Vincenza Snow; Katherine Sherif; Mark Aronson; Kevin B Weiss; Douglas K Owens Journal: Ann Intern Med Date: 2007-04-03 Impact factor: 25.391
Authors: Dennis G Fryback; Natasha K Stout; Marjorie A Rosenberg; Amy Trentham-Dietz; Vipat Kuruchittham; Patrick L Remington Journal: J Natl Cancer Inst Monogr Date: 2006
Authors: Rianne de Gelder; Elisabeth van As; Madeleine M A Tilanus-Linthorst; Carina C M Bartels; Rob Boer; Gerrit Draisma; Harry J de Koning Journal: Int J Cancer Date: 2008-08-01 Impact factor: 7.396
Authors: Jeffrey A Tice; Steven R Cummings; Rebecca Smith-Bindman; Laura Ichikawa; William E Barlow; Karla Kerlikowske Journal: Ann Intern Med Date: 2008-03-04 Impact factor: 25.391
Authors: Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur Journal: Radiology Date: 2014-11-12 Impact factor: 11.105
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Jeroen J van den Broek; Nicolien T van Ravesteyn; Jeanne S Mandelblatt; Hui Huang; Mehmet Ali Ergun; Elizabeth S Burnside; Cong Xu; Yisheng Li; Oguzhan Alagoz; Sandra J Lee; Natasha K Stout; Juhee Song; Amy Trentham-Dietz; Sylvia K Plevritis; Sue M Moss; Harry J de Koning Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Clyde B Schechter; Aimee M Near; Jinani Jayasekera; Young Chandler; Jeanne S Mandelblatt Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Brian L Sprague; Natasha K Stout; Clyde Schechter; Nicolien T van Ravesteyn; Mucahit Cevik; Oguzhan Alagoz; Christoph I Lee; Jeroen J van den Broek; Diana L Miglioretti; Jeanne S Mandelblatt; Harry J de Koning; Karla Kerlikowske; Constance D Lehman; Anna N A Tosteson Journal: Ann Intern Med Date: 2015-02-03 Impact factor: 25.391
Authors: Jeroen J van den Broek; Nicolien T van Ravesteyn; Eveline A Heijnsdijk; Harry J de Koning Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583